VolitionRX Limited VNRX
- Market cap
- $6.9M
- P/E
- 0.0×
Follow VNRX
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 61.00 | 41.60 | 28.80 | 37.80 | 44.40 | 58.20 | 26.20 | 11.00 | 8.60 | 4.40 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 117.20 | 109.00 | 80.00 | 136.80 | 104.00 | 133.40 | 66.00 | 54.00 | 24.60 | 18.80 |
High Price
|
|||
| 22 | 37 | 44 | 50 | 65 | 83 | 104 | 110 | 85 | 75 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
Revenue
|
|||
| 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Gross Margin
|
|||
| (12) | (15) | (18) | (16) | (20) | (27) | (31) | (36) | (27) | (24) |
EBT
|
|||
| 0.00% | 0.00% | 0.00% | (94,146.78%) | (152,233.58%) | (29,988.67%) | (9,986.46%) | (4,601.72%) | (2,209.81%) | (1,360.62%) |
EBT Margin
|
|||
| (12) | (15) | (18) | (16) | (20) | (27) | (31) | (36) | (27) | (24) |
Net Income
|
|||
| 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 |
Depreciation
|
|||
| 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.03 | 0.11 | 0.22 | 0.29 | 0.32 |
Revenue/Sh
|
|||
| (10.40) | (11.20) | (11.40) | (8.20) | (9.00) | (10.20) | (11.00) | (10.00) | (6.20) | (4.40) |
Earnings/Sh
|
|||
| (7.69) | (9.24) | (9.39) | (6.50) | (7.27) | (7.92) | (5.52) | (5.07) | (5.98) | (3.68) |
Cash Flow/Sh
|
|||
| (0.36) | (1.08) | (0.19) | (0.26) | (0.73) | (0.37) | (0.57) | (0.30) | (0.13) | (0.02) |
Capex/Sh
|
|||
| (8.05) | (10.32) | (9.58) | (6.76) | (8.00) | (8.29) | (6.09) | (5.38) | (6.12) | (3.70) |
Free CF/Sh
|
|||
| 18.37 | 7.55 | 7.74 | 7.25 | 7.20 | 6.73 | (1.13) | (2.45) | (6.03) | (6.66) |
Book Value/Sh
|
|||
| 1 | 1 | 2 | 2 | 2 | 3 | 3 | 4 | 4 | 5 |
Shares
|
|||
| — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | 2,649.26 | 13,144.72 | 1,837.11 | 431.74 | 96.47 | 42.09 | 16.08 |
PS Ratio
|
|||
| — | — | — | 13.08 | 10.81 | 9.33 | 0.00 | 0.00 | 0.00 | 0.00 |
PB Ratio
|
|||
| — | — | — | 2,456.46 | 11,995.87 | 1,648.20 | 410.25 | 76.48 | 43.61 | 21.73 |
EV/Sales
|
|||
| — | — | — | (12.94) | (8.85) | (6.78) | (7.44) | (3.09) | (2.03) | (1.87) |
EV/FCF
|
|||
| (9) | (12) | (15) | (13) | (16) | (21) | (15) | (18) | (26) | (20) |
Op' Cash Flow
|
|||
| 0 | (1) | 0 | (1) | (2) | (1) | (2) | (1) | (1) | 0 |
Capex
|
|||
| (9) | (14) | (15) | (13) | (18) | (22) | (17) | (19) | (26) | (20) |
FCF
|
|||
| 20 | 8 | 12 | 14 | 14 | 15 | (5) | 13 | (4) | (10) |
Working Cap'
|
|||
| 1 | 3 | 3 | 3 | 4 | 4 | 4 | 5 | 5 | 11 |
Total Debt
|
|||
| (20) | (7) | (10) | (14) | (15) | (17) | (7) | (15) | 2 | 10 |
Net Debt
|
|||
| 21 | 10 | 12 | 14 | 16 | 18 | (3) | (9) | (26) | (36) |
Sh' Equity
|
|||
| (73.39%) | (75.05%) | (112.16%) | (83.03%) | (85.80%) | (99.98%) | (132.22%) | (152.75%) | (144.41%) | (286.58%) |
ROA
|
|||
| (915.17%) | (371.41%) | (609.86%) | (1,468.05%) | (1,476.85%) | (2,457.42%) | 0.00% | 0.00% | 0.00% | 0.00% |
ROIC
|
|||
| (87.48%) | (94.88%) | (162.99%) | (122.24%) | (133.49%) | (157.66%) | (414.78%) | 596.65% | 154.90% | 75.71% |
ROE
|
|||
VolitionRX Limited peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ICCM IceCure Medical Ltd. | $6.5M | 0.0× | Compare |
| NVNO enVVeno Medical Corporation | $6.3M | 0.0× | Compare |
| AMIX Autonomix Medical, Inc. | $7.9M | 0.0× | Compare |
| CODX Co-Diagnostics, Inc. | $8.3M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| INBS Intelligent Bio Solutions Inc. | $5.7M | 0.0× | Compare |
| WOK WORK Medical Technology Group LTD | $8.9M | — | Compare |
| TBIO Telesis Bio Inc. | $5.3M | 0.0× | Compare |
| VVOS Vivos Therapeutics, Inc. | $4.9M | 0.0× | Compare |
VolitionRX Limited (VNRX) key facts
- VolitionRX Limited (VNRX) is a Medical Devices company in the Healthcare sector, listed on NYSE American.
- VolitionRX Limited’s revenue for fiscal 2025 (year ended December 2025) was $1.7 million, up 40.0% from fiscal 2024.
- As of September 25, 2026, VNRX traded at $0.26, a market capitalization of $6.9 million.
- Return on equity was 75.7% and debt-to-equity -0.33.
VolitionRX Limited (VNRX) Latest News
17 Sep
VolitionRx Limited releases additional details along with a video covering the DETECSEPS program launch in France. The DETECSEPS program launch in France may boost VolitionRx market access and near-term revenue without altering long-term company trajectory.
14 Sep
VolitionRx prepays outstanding balance on $7,500,000 Lind Senior Secured Convertible Promissory Note dated May 20, 2025. Reviews papers, posters, and videos released mid-2026. Sysmex collaboration counts as third recent agreement in human space. Debt prepayment plus third collaboration signals improved liquidity and commercial traction without altering core trajectory.
VolitionRx prepays outstanding balance on $7,500,000 Lind Senior Secured Convertible Promissory Note dated May 20, 2025. Papers, posters, and videos released in mid-2026 reviewed. Sysmex collaboration marks third recent agreement in human space. Debt prepayment strengthens balance sheet while multiple collaborations indicate moderate expansion in partnerships and positioning.
VolitionRx Limited pre-paid in full its $7.5 million senior secured convertible promissory note due May 20, 2027. Early settlement of the convertible note reduces long-term debt and potential dilution for VolitionRx Limited.
10 Sep
VolitionRX Limited presented data on early stage I solid cancer detection at the ESMO MAP Conference. Conference presentation on stage I cancer detection offers visibility for VolitionRX but remains early-stage without immediate revenue or approval effects.
27 Aug
VolitionRx Limited validates key diagnostics, expanding addressable markets for its tests. Diagnostic validations expand VolitionRx addressable markets and support revenue growth potential.
26 Aug
VolitionRx Limited advances commercial momentum and multi-pillar execution across total addressable markets exceeding $27 billion. Commercial momentum in markets over $27 billion signals major strategic progress likely to boost long-term growth and investor sentiment.
VolitionRX Limited achieved landmark clinical validation of its Nu.Q® NETs biomarker for sepsis. Landmark sepsis validation of Nu.Q NETs biomarker signals major diagnostic market entry and revenue potential for VolitionRX.
20 Aug
VolitionRX Limited (VNRX) held its Q2 2026 earnings call. Earnings call provides financial results and outlook that can shift near-term investor views.
14 Aug
VolitionRx Limited held its Q2 2026 earnings call covering quarterly financial results and company outlook. Earnings call delivers financial updates and guidance with moderate influence on near-term valuation and sentiment.
13 Aug
VolitionRx Limited announced its second quarter 2026 financial results and business update. Quarterly financial results typically produce moderate effects on valuation and sentiment without fundamentally shifting long-term trajectory.
12 Aug
VolitionRX Limited demonstrated utility of its rapid point-of-care finger-prick test in sepsis patients. Successful test demonstration in sepsis expands product applicability and supports revenue growth potential.
5 Aug
VolitionRX Limited published the first peer-reviewed paper on its Capture-Seq™ liquid biopsy technology. Peer-reviewed publication validates new Capture-Seq technology and strengthens VolitionRX innovation and market positioning.
30 Jul
VolitionRX Limited advances its Nu.Q NETs platform towards commercialization. Platform commercialization progress signals major product development and market entry steps for the company.
11 Jul
VolitionRx (VNRX) stock receives fair value boost from analysts who remain split on Nu.Q execution prospects. Analyst fair value revision may shift short-term VNRX sentiment without altering core operations.
7 Jul
VolitionRx Limited announced data demonstrating the prognostic value of its Nu.Q® Cancer Test. Positive prognostic data on core Nu.Q test supports clinical adoption potential and may lift near-term investor sentiment.
17 Jun
VolitionRx Limited announces collaboration with Sysmex. Collaboration may improve VolitionRx access to markets and technology but lacks details on scope or financial terms.
3 Jun
VolitionRx Limited files new patent protecting its Nu.Q® NETs Test for Ebola triage and treatment monitoring. Patent filing expands Nu.Q NETs test applications into Ebola triage potentially aiding product positioning and future revenue.
27 May
VolitionRx Limited advances commercial initiatives and multi-pillar execution across total addressable markets exceeding $27 billion. Commercial momentum and multi-pillar execution in markets over $27 billion signal potential for accelerated revenue growth and stronger competitive positioning.
15 May
VolitionRX Ltd reported a revenue surge in its Q1 2026 earnings call alongside strategic developments aimed at advancing its core diagnostics platform and market expansion. Revenue surge and strategic updates signal major financial and operational progress likely to boost investor sentiment and growth trajectory.
VolitionRx Limited (VNRX) held its Q1 2026 earnings call covering financial results, operational updates and forward outlook. Earnings call delivers core financial metrics and guidance that typically move investor sentiment and share price.
14 May
VolitionRx Limited announced first quarter 2026 financial results and provided a business update. Quarterly financial results and business updates represent major disclosures that can significantly alter investor sentiment and company trajectory.
29 Apr
VolitionRX Limited announces breakthrough finger-prick detection of nucleosomes, expanding global market potential for sepsis testing. Breakthrough finger-prick nucleosome detection revolutionizes sepsis diagnostics, significantly boosting VNRX's market reach and competitive edge.
27 Apr
VolitionRX Limited (VNRX) expects milestones in 2026 and plans to release year-end 2025 results. Stockholders approved a reverse stock split at a special meeting, with the Board authorizing a 1-for-20 reverse split effective April 28th. The 1-for-20 reverse split alters share structure and market sentiment, while 2026 milestones suggest moderate future potential.
23 Apr
VolitionRx Limited announces NYSE American acceptance of its compliance plan. NYSE American acceptance averts delisting risk and enhances investor confidence and market liquidity.
20 Apr
VolitionRX Limited (VNRX) launches rNuQ™ Webshop, broadening its product range to enhance accessibility and commercialization of NuQ® assays. Launching a dedicated webshop expands direct sales channels for rNuQ® products, significantly enhancing revenue potential and market reach.
2 Apr
VolitionRX Ltd (VNRX) Q4 2025 earnings call highlighted strong revenue growth and strategic advancements. Strong revenue growth and strategic developments indicate significant positive shifts in financial performance and market positioning.
1 Apr
VolitionRx Limited (VNRX) released Q4 2025 earnings call summary covering financial results, operational updates, and forward guidance. Q4 earnings call summary reveals financial performance and strategic outlook with moderately noticeable influence on market sentiment.
31 Mar
VolitionRx Limited announced full fiscal year 2025 financial results and business update. Full-year financial results and business updates represent major disclosures that can significantly sway investor sentiment and stock trajectory.
VolitionRx Limited (VNRX) secures EUR 2.0 million in non-dilutive funding from regional government agencies in Belgium. EUR 2.0 million non-dilutive funding provides moderate financial support for operations without shareholder dilution.